Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label Positron Emission Tomography Study With Selective Beta Amyloid Radioligand (18Fluor)AZD4694 to Assess the Effects of Varying Mass of AZD4694 on Radioligand Binding Parameters in Healthy Volunteers and Patients With Alzheimer's Disease

NCT01325402 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01325402
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01325402 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label Positron Emission Tomography Study With Selective Beta Amyloid Radioligand (18Fluor)AZD4694 to Assess the Effects of Varying Mass of AZD4694 on Radioligand Binding Parameters in Healthy Volunteers and Patients With Alzheimer's Disease
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2011
Completion date
November 30, 2012
Enrollment
16 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

maximum diagnostic mass of [18fluor]azd4694